Action MTACU MEDH ACQU
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues MEDH ACQU Nasdaq

Actions

MTACU

US58507N2045

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
MEDH ACQU : STANDBY EQUITY PURCHASE AGREEMENT - Form 8-K
MedTech Acquisition, TriSalus Life Sciences Complete Merger
MedTech Acquisition Corporation(NasdaqCM:MTAC) dropped from NASDAQ Composite Index
Trisalus Life Sciences Inc. completed the acquisition of MedTech Acquisition Corporation from Medtech Acquisition Sponsor LLC, Magnetar Financial LLC and others.
Top Premarket Gainers
MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders
MedTech Acquisition : Material Event - Form 8-K
MedTech Acquisition Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
MEDTECH ACQUISITION CORP : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
MedTech Acquisition Corporation announced that it has received $0.137375 million in funding
TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD Method with the TriNav Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting
TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting
TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases At the Asco 2023 Annual Meeting
MEDTECH ACQUISITION CORP : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
MedTech Acquisition Corporation announced that it expects to receive $17.85502 million in funding
MedTech Acquisition Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023
TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD Method in Stage IV Uveal Melanoma Patients with Liver Metastases
MEDTECH ACQUISITION CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD™ Method in Stage IV Uveal Melanoma Patients With Liver Metastases
MEDTECH ACQUISITION CORP : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action MTAC
  4. Action MTACU
  5. Actualités MEDH ACQU
  6. Autres langues